• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

    2.250 +0.100 (+4.65%)
    Streaming Delayed Price Updated: 3:57 PM EST, Dec 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,383
    Open 2.180
    Bid (Size) 2.210 (1,000)
    Ask (Size) 2.260 (300)
    Prev. Close 2.150
    Today's Range 2.110 - 2.300
    52wk Range 1.880 - 12.06
    Shares Outstanding 3,139,861
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants ↗
    Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring. 
    Via Benzinga
    News headline image
    Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
     
    Via Benzinga

    Performance

    YTD
    -79.2%
    -79.2%
    1 Month
    -10.4%
    -10.4%
    3 Month
    -0.9%
    -0.9%
    6 Month
    -39.5%
    -39.5%
    1 Year
    -79.0%
    -79.0%

    More News

    Read More
    News headline image
    Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
    From Alzamend Neuro, Inc.
    Via GlobeNewswire
    News headline image
    Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
    From Alzamend Neuro, Inc.
    Via GlobeNewswire
    News headline image
    Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
    From Alzamend Neuro, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Top movers in Friday's session ↗
    Via Chartmill
    News headline image
    Traders are paying attention to the gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor’s Drink Expansion – More Stocks Inside
    Via AB Newswire
    Topics Economy
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled ↗
    Via Stocktwits
    News headline image
    Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone ↗
    Via Benzinga
    News headline image
    Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Via Chartmill
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue ↗
    Via Benzinga
    BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001
    Via Investor Brand Network
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
    From Alzamend Neuro, Inc.
    Via GlobeNewswire
    News headline image
    Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
    From Alzamend Neuro, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill

    Frequently Asked Questions

    Is Alzamend Neuro, Inc. - Common Stock publicly traded?
    Yes, Alzamend Neuro, Inc. - Common Stock is publicly traded.
    What exchange does Alzamend Neuro, Inc. - Common Stock trade on?
    Alzamend Neuro, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Alzamend Neuro, Inc. - Common Stock?
    The ticker symbol for Alzamend Neuro, Inc. - Common Stock is ALZN on the Nasdaq Stock Market
    What is the current price of Alzamend Neuro, Inc. - Common Stock?
    The current price of Alzamend Neuro, Inc. - Common Stock is 2.250
    When was Alzamend Neuro, Inc. - Common Stock last traded?
    The last trade of Alzamend Neuro, Inc. - Common Stock was at 12/05/25 03:57 PM ET
    What is the market capitalization of Alzamend Neuro, Inc. - Common Stock?
    The market capitalization of Alzamend Neuro, Inc. - Common Stock is 7.06M
    How many shares of Alzamend Neuro, Inc. - Common Stock are outstanding?
    Alzamend Neuro, Inc. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.